Rapid Functional Testing of Protein C with Protac®, a New Protein C Activator (2023)

Cited by (140)

  • Components of snake venom in medicine: from the symbolic staff of Asclepius to research and concrete medical application

    2018, International Journal of Biochemistry and Cell Biology

    Quote excerpt:

    They show high sequence similarity to other serine proteases (Stocker et al., 1986). Their insensitivity to endogenous inhibitors qualifies them as a diagnostic tool to identify protein C-related bleeding disorders, for example, the protein C activator Protac® from the southern copperhead snake (Agkistrodon contortrix contortrix) (Gempeler-Messina et al. , 2001; Martinoli and Stocker, 1986). An example of an anticoagulant thrombin inhibitor is the non-enzymatic bonerojaracin type C-like lectin from Bothrops jararaca, which acts in two ways: it inhibits prothrombin activation (Zingali et al., 2001) and thrombin-induced platelet aggregation (Arocas et al. al., 2001). al., 2001). al., 1996).

    Both mythologically and logically, snakes have always fascinated man. Snakes inspired awe and fear, not only because of the graceful movement of their limbless bodies, but also because of the power of their deadly venoms. On a practical level, the World Health Organization (WHO) classified snake envenomation as a high priority neglected disease in 2017, because snakes cause up to 2.7 million venom bites, about 100,000 victims, and about three times more human inability. Venom from venomous snakes is a cocktail of potent compounds that specifically and specifically target numerous essential molecules with high potency. Integrating the individual effects of all toxins in fatal dysfunctions of nearly all organ systems. It is this potency and specificity of each venom component that, after analyzing its structure and activity, may serve as a potential lead structure for chemical mimicry. These toxin mimics can help pharmaceutically influence a specific bodily function in the interest of human health. In this review article, we present some examples of snake venom components that have fueled the development of new pharmaceutical compounds. Furthermore, we will provide examples where such snake toxin-derived mimetics are in clinical use, in studies or are considered for further pharmaceutical use, particularly in the fields of hemostasis, thrombosis, coagulation and metastasis. This makes it clear why a snake nevertheless took its symbolic place on Asclepius' staff, and rightly so.

  • The influence of the endothelial protein C receptor on thrombin formation and clot lysis

    2017, Thrombosis Research

    Quote excerpt:

    Clinically, impairment of the PC anticoagulant pathway has been associated with an increased risk of venous thromboembolism [8-10]. PC deficiency, in which individuals have a congenital or acquired reduction in PC antigen and/or PC activity, is an independent risk factor for thrombosis and can be caused by ex vivo activation of PC by Protac, an activator found in snake venom. identified [11, 12]. ]. However, PC activation in vivo is accelerated by binding of PC to EPCR in the vascular endothelium [4].

    When thrombin binds to thrombomodulin (TM), it becomes a potent protein C activator (PC) and an inhibitor of thrombin-activatable fibrinolysis (TAFI). PC activation is enhanced when PC binds to the endothelial protein C receptor (EPCR). Activated protein C (APC) inhibits thrombin production while activated TAFI (TAFIa) attenuates fibrinolysis. To determine the impact of reduced EPCR function on thrombin formation and fibrinolysis, we generated cells that express TM and an EPCR variant (R96C) that does not bind PC.

    To determine the impact of EPCR on APC and TAFIa generation and effects on thrombin generation and fibrinolysis, we performed thrombin generation and clot lysis assays in the presence of cells expressing wild-type TM and EPCR (WT cells) or wild-type -TM Express . and the EPCR variant R96C (R96C cells).

    In the presence of R96C cells, thrombin generation is increased in normal plasma due to decreased PC activation compared to WT cells. Furthermore, in normal plasma, clot lysis is delayed in the presence of R96C cells, although TAFI activation is not enhanced. In PC-deficient plasma, clot lysis is delayed in the presence of WT and R96C cells due to increased TAFI activation.

    (Video) Targeted protein degradation (via PROTACs, molecular glues, etc.) and stabilization (via DUBTACs)

    We show that impaired EPCR function can be detected by thrombin formation and clot lysis assays in cells expressing TM and EPCR. We have also shown that EPCR deficiency has procoagulant effects, resulting in a delay in clot lysis.

  • A snakebite causes hemostasis/thrombosis

    2013, Thrombosis Research

    Quote excerpt:

    The conversion of protein C to activated protein C (APC) is important because APC regulates the rate of clotting by inactivating factors VIIIa and Va. Protein C activators have been isolated from many viper species [27], the best studied form being the North American copperhead Agkistrodon contortrix contortrix, from which the Protac® diagnostic tool was developed [28]. Protac® allows the determination of Protein C by conversion to APC, whose activity can be determined by activated partial thromboplastin time or using a chromogenic assay.

    Snake venom toxins have evolved to affect many physiological systems in prey animals, including hemostasis and thrombosis. These toxins belong to a variety of protein families and can initiate or inhibit multiple steps in the coagulation or platelet aggregation pathway with remarkable specificity. This specificity for vertebrate molecular targets has made them extremely useful for diagnosing human diseases or as molecular scalpels in physiological studies. The large number of toxins that have not yet been characterized represents an important potential source for new toxins and subsequent cardiovascular therapies and diagnostics.

  • Snake Venom Protein C Activators

    2013 Proteolytic Enzymes Handbook

  • Reduced levels of activated protein C as a clinical predictor in patients with ST-segment elevation myocardial infarction

    2008, American Heart Journal

    Quote excerpt:

    The mixture was then incubated at 37°C for 4 minutes. After 3 minutes, 0.025 mol/L of CaCl2 (100 μL) was added and APC levels were quantified blindly using the activated partial thromboplastin time measurement method.14 Activated PC levels correlated with time of activated partial thromboplastin in standard plasma.

    Circulating markers indicative of atherosclerotic plaque instability may have diagnostic and prognostic value in patients with acute coronary syndromes. We evaluated activated protein C (APC), which has antithrombotic, anti-inflammatory, and profibrinolytic properties, as a potential clinical predictor of ST-segment elevation myocardial infarction (STEMI), including return of spontaneous circulation after sudden cardiac arrest.

    (Video) Craig Crews - Dana-Farber Targeted Degradation Webinar Series

    Patients with STEMI whose APC was measured on arrival at the emergency department were included in this study (n = 335). The primary endpoint was in-hospital death from any cause.

    The APC value ranged from 29% to 142%, with a median of 80%. The unadjusted mortality rate progressively increased with decreasing APC values ​​(33.7% in the 1st quartile, 12.7% in the 2nd quartile, 6.0% in the 3rd quartile and 3.6% in the 4th quartile).P< 0.001). This association remained significant in subgroups of patients with STEMI alone (P= 0.04) or with spontaneous cycle return (P= 0.01). After adjusting for independent predictors of in-hospital death, the odds ratio of death among those in the first quartile of APC scores was 9.4 (95% CI 1.1-81.6).P= 0.04). An APC cutoff value of 65% had the highest combined sensitivity and specificity in predicting death.

    Measuring APC levels provides predictive information for use in risk stratification across the STEMI spectrum. Decreased APC levels may be a consistent feature in patients at high risk of dying after STEMI.

  • Crystallization and preliminary X-ray crystallographic studies of Protac®, a commercial protein C activator isolated from the venom of Agkistrodon contortrix contortrix

    2005, Biochemistry and Biophysics Journal – Protein and Proteomics

    The protein C pathway plays an important role in controlling and regulating the blood clotting cascade and prevents the clotting process from spreading to the endothelial surface. In physiological systems, protein C activation is catalyzed by thrombin, which requires thrombomodulin as a cofactor. The protein C activator ofAgkistrodon contortrix contortrixIt acts directly on the protein C zymogen, converting it into the active form independently of thrombomodulin. Suitable Crystals of Protein C Activator fromAgkistrodon contortrix contortrixwere recovered from a solution containing 2M ammonium sulfate as a precipitant and these crystals were bent in a synchrotron beamline to a resolution of 1.95 Å. The crystalline arrangement belongs to the monoclinic space group C2 with unit cell dimensionsA=80,4,B= 63.3 inchesC=48,2 A,A=C=90,0° emB=90,8°.

View all citation articles on Scopus

Selected Items (6)

  • Research Article

    Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for first plasma resuscitation after life-threatening haemorrhage

    Journal of the American College of Surgeons, Band 220, Nummer 5, 2015, S. 872–879

    Prehospital resuscitation with crystalloids exacerbates fibrinolysis, which is associated with high mortality. We hypothesize that, compared to crystalloid resuscitation, plasma prevents hyperfibrinolysis in an environment rich in tissue plasminogen activator (tPA), preserving essential proteins for the regulation of fibrinolysis.

    Healthy subjects donated blood that was tested using native (non-activated) thrombolastography (TEG). Whole blood was mixed in progressive dilutions with normal saline (NS) or low platelet plasma (PPP). Tissue plasminogen activator was added to promote a fibrinolytic environment. In a separate experiment, PPP was passed through a 100 kDa filter and the remaining liquid at the top of the filter (TFP) and below the filter (BFP) was obtained. Whole blood was diluted to 50% with TFP, BFP and NS and tested with a tPA-TEG challenge. TFP and BFP were tested for protein concentration and protein composition.

    Normal saline and PPP dilution of whole blood without tPA had no effect on clot lysis at 30 minutes (LY30) (NS Spearman's rho 0.300, p=0.186 and PPP 0.294, p=0.288). The addition of tPA increased the NS dilution percentage of LY30 whole blood (0.844, p<0.001), but not significantly (0.270, p=0.202) with PPP dilution. The difference in LY30 between whole blood and PPP-diluted whole blood (mean change -1.05, 95% CI, -9.42 to 7.33) was similar to that for TFP (1.23, 95% CI, -5 .20 to 7.66, p=0.992). However, both BFP (37.65, 95% CI 24.47 to 50.82, p=0.001) and NS (47.36, 95% CI 34.3 to 60.45, p <0.001) showed an increase accentuated in fibrinolysis compared to PPP.

    Dilution of crystalloids and whole blood plasma does not enhance fibrinolysis. However, NS dilution of whole blood increases susceptibility to tPA-mediated fibrinolysis. Plasma resuscitation, simulated by plasma dilution of whole blood, reduces the increased susceptibility to tPA-mediated fibrinolysis. The advantages of plasma resuscitation lie in the preservation of plasma proteins.

  • Research Article

    Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts

    Alzheimer and Dementia, Volume 13, Number 11, 2017, pp. 1217-1225

    (Video) Disrupting Membrane Proteins and Receptors Function with PROTAC Drugs by Tauseef R Butt

    A family history (FH) of Alzheimer's disease (AD) affects mitochondrial function and may modulate the action of the 40 kDa mitochondrial outer membrane translocase (TOMM40) rs10524523 ('523) amnesic poly-T length.

    For 912 middle-aged and 365 middle-aged adults on the AD spectrum, mixed linear models measured HF andTOMM40'523 Interactions in memory and global cognition between baseline and up to 10 years later. A biomarker of CSF mitochondrial function was also evaluated.

    In FH-negative participants, preservation of memory and global cognition per gene dose was observed in 'very long' and 'short' carriers. In FH positives, an opposite decrease in gene dose was seen in very long carriers compared to short carriers. Maternal FH was a stronger predictor in middle-aged participants but not in middle-aged participants. Similar gene dose effects were observed for the mitochondrial biomarker aspartate aminotransferase.

    These results may clarify conflicting resultsTOMM40Poly-T length and AD-related decline.

  • Research Article

    Controlling cellular behavior with peptide nanopatterns

    Journal of Colloid and Interface Science, janeiro 430, 2014, blz. 207-213

    Correct cell polarization and division is critical for a developing organism and a number of later biological processes, including cancer metastasis, cell migration and organelle organization. Both cellular behaviors are complex and influenced by a number of external factors, including the extracellular matrix (ECM), physical-mechanical and hydrodynamic forces. In particular, the ECM acts as a dynamic three-dimensional scaffolding support for tissue segregation and cell adhesion. Although the cells are only microns in size, they detect and respond to dynamic nanoarchitectural changes in the ECM. To better understand these complex processes, model substrates were developed to mimic the spatial representation of ligands as gradients and unicellular patterns. However, until now, little attention has been paid to the interaction of ligand affinity, ligand density and ligand surface area at the nanoscale on cellular behavior due to the lack of synergistic surface chemistry, microscopy, cell biology and nanostructuring technologies. In this report, we develop nanostructured biospecific peptide matrix substrates to study how the nanoenvironment drives cellular behavior using parallel nanolithography.

  • Research Article

    Elevation of urinary methylmolonic acid induces suppression of megalin-mediated endocytic cycles during vitamin B12 deficiency

    Biochemical and Biophysical Research Communications, Band 465, Ausgabe 2, 2015, S. 206–212

    Megalin is a scavenger receptor involved in the endocytosis of a highly diverse group of ligands, including B vitamins12. We found megalin accumulation near the apical region in vitamin B proximal renal tubule cells12defective mice. Interestingly, vitamin B12The concentrations also controlled renal reabsorption of retinol-binding protein. Using yolk sac L2 cells, megalin is localized to the submembrane compartment by methylmalonic acid (MMA), which accumulates during vitamin B2 accumulation12Lack. Furthermore, MMA inhibited megalin-mediated endocytosis via the YWTD repeat motif in a megalin ectodomain. Therefore, megalin endocytosis can be regulated by MMA.

    (Video) [Recorded Webinar] PROTAC — Developing New Therapies through Targeted Protein Degradation
  • Research Article

    NF-κB is activated from endosomal compartments in human monocytes treated with antiphospholipid antibodies

    Journal of Thrombosis and Heostasis, Band 12, Ausgabe 5, 2014, S. 779–791

    Antiphospholipid antibody syndrome (APS) is an autoimmune disease associated with arterial or venous thrombosis and/or recurrent fetal loss caused by pathogenic antiphospholipid antibodies (aPLA). We have recently shown that Toll-like receptor 2 (TLR2) and CD14 contribute to the activation of aPLA monocytes.

    Study the mechanisms of cell activation by aPLA, which leads to procoagulant and proinflammatory responses.

    For this study, we used antibodies purified from the plasmas of 10 different patients with APS and healthy donors. We show that aPLA, but not control IgG, is located on human monocytes along with TLR2 and TLR1 or TLR6. Blocking antibodies against TLR2, TLR1, or TLR6, but not against TLR4, reduced the TNF and tissue factor (TF) response to aPLA. Pharmacological and siRNA approaches revealed the importance of clathrin/dynamin-dependent endocytic signaling in cellular activation by aPLA. Furthermore, soluble aPLA induced NF-κB activation, whereas aPLA granules that were not internalized did not activate NF-κB. The internalization of aPLA in monocytes and the activation of NF-κB were dependent on the presence of CD14.

    We show that TLR2 and its co-receptors TLR1 and TLR6 contribute to the pathogenicity of aPLA, that aPLA is internalized via clathrin- and CD14-dependent endocytosis, and that endocytosis is required for NF-κB activation. Our results contribute to a better understanding of APS and offer a possible therapeutic approach.

  • Research Article

    Measuring apixaban and rivaroxaban activity using rotational thromboelastometry

    Thrombosis Research, Volume 134, Issue 4, 2014, pp. 918–923

    Routine drug monitoring is not required for the two new direct factor Xa inhibitors, apixaban and rivaroxaban. Quickly available test results can be helpful in case of bleeding or before emergency surgery.

    The aim of this study was to evaluate the applicability of two modifications of rotational thrombus elastometry (ROTEM®): ROTEM® activated by low tissue factor (LowTF-ROTEM®) and ROTEM® activated by prothrombinase-induced clotting time (PiCT®-ROTEM). . ® ) for determination of apixaban and rivaroxaban in vitro and ex vivo.

    Blood samples from 20 volunteers were spiked with apixaban/rivaroxaban to obtain samples with increasing drug concentrations ranging from 50-400 ng/mL. ROTEM® assays modified with LowTF and PiCT® and the determination of the corresponding anti-factor Xa activity were performed in duplicate on 280 samples. The LowTF-ROTEM® test was performed on samples from 20 patients on apixaban or rivaroxaban therapy and 20 control subjects.

    There was a strong correlation between apixaban/rivaroxaban plasma concentrations and the parameters LowTF-ROTEM® time to clot (CT; Spearman correlation coefficient (SCC) 0.81 and 0.81, respectively) and time to maximum velocity (t , MaxVel; SCC: 0.81 and 0.80, respectively). ) and a low to moderate correlation for the PiCT®-ROTEM® CT parameters (SCC: 0.38 and 0.59, respectively) and t,MaxVel. (0.51 and 0.69, respectively) in in vitro experiments. LowTF-ROTEM-CT was significantly longer in patients receiving apxiaban or rivaroxaban therapy compared to controls.

    (Video) Amide-to-Ester Substitution as a Strategy for Optimising PROTAC Permeability and Cellular Activity

    LowTF–ROTEM® can be a valuable diagnostic tool to quickly determine the effect of apixaban and rivaroxaban at the point of care.

Copyright © 1986 Published by Elsevier Ireland Ltd.


What does high protein C functional mean? ›

What do the results mean? Higher than normal levels of protein C or S are not known to cause any health problems. Lower than normal levels of protein C or S, or proteins that aren't working well, mean that you have a higher risk of developing a blood clot.

What causes high protein C in blood? ›

Possible Causes

Chronic (long-term) inflammation or inflammatory disorders. Viral infections such as hepatitis B, hepatitis C or HIV/AIDS. Blood cancers such as multiple myeloma or certain types of lymphoma. Severe liver or kidney disease.

What is the normal range for protein C functional? ›

The normal range of protein C activity in healthy adults is between 65 to 135 IU dL-1. Patients with mild protein C deficiency have activity levels between 20 IU dL-1 and the lower limit of normal values, as determined by age.

What does protein C activity mean? ›

Protein C helps control blood clotting. A lack of this protein or a problem with the function of this protein may cause blood clots to form in veins. The test is also used to screen relatives of people who are known to have protein C deficiency. It may also be done to find the reason for repeated miscarriages.


1. Webinar – Understanding PROTACs-Mediated Targeted Protein Degradation
(BPS Bioscience)
2. Alessio Ciulli - Dana-Farber Targeted Degradation Webinar Series
(Dana-Farber TPD)
3. Ning Zheng - Dana-Farber Targeted Degradation Webinar Series
(Dana-Farber TPD)
4. Challenges and Opportunities in PROTAC vs Small Molecules Development - Round Table discussion
(European Federation for Medicinal Chemistry)
5. COMy Online - 2020 Session 13
(International Academy for Clinical Hematology IACH)
6. Drug Discovery | Biomarkers in Drug Development: Protein Fingerprint | Nordic Bioscience
(Nordic Bioscience)


Top Articles
Latest Posts
Article information

Author: Zonia Mosciski DO

Last Updated: 05/07/2023

Views: 6154

Rating: 4 / 5 (51 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Zonia Mosciski DO

Birthday: 1996-05-16

Address: Suite 228 919 Deana Ford, Lake Meridithberg, NE 60017-4257

Phone: +2613987384138

Job: Chief Retail Officer

Hobby: Tai chi, Dowsing, Poi, Letterboxing, Watching movies, Video gaming, Singing

Introduction: My name is Zonia Mosciski DO, I am a enchanting, joyous, lovely, successful, hilarious, tender, outstanding person who loves writing and wants to share my knowledge and understanding with you.